News

News

December 27, 2016

IMMUNOMEDICS ANNOUNCES ACHIEVEMENT OF PATIENT ENROLLMENT INTO SINGLE-ARM PHASE 2 STUDY WITH SACITUZUMAB GOVITECAN (IMMU-132) IN TRIPLE-NEGATIVE BREAST CANCER

December 22, 2016

IMMUNOMEDICS AWARDED ADDITIONAL INTELLECTUAL PROPERTY PROTECTION FOR IMMU-140, AN ANTIBODY-DRUG CONJUGATE WITH DUAL-THERAPEUTIC POTENTIAL

December 12, 2016

IMMUNOMEDICS ANNOUNCES NOVEL IMMUNO-ONCOLOGY PROGRAM TARGETING TROP-2-EXPRESSING CANCERS

December 6, 2016

IMMUNOMEDICS INTRODUCES NEW ANTIBODY-DRUG CONJUGATE AT ANNUAL MEETING OF AMERICAN SOCIETY OF HEMATOLOGY

November 28, 2016

IMMUNOMEDICS POSTPONES 2016 ANNUAL MEETING OF STOCKHOLDERS

November 18, 2016

IMMUNOMEDICS COMMENTS ON RECEIPT OF DIRECTOR NOMINATIONS

November 15, 2016

IMMUNOMEDICS EXPANDS ANTIBODY-DRUG CONJUGATE PROGRAM TO POTENTIALLY ADDRESS MOST OF HUMAN CANCERS

November 14, 2016

IMMUNOMEDICS TO PROVIDE CLINICAL UPDATE ON SACITUZUMAB GOVITECAN (IMMU-132) IN TRIPLE-NEGATIVE BREAST CANCER AT SAN ANTONIO BREAST CANCER SYMPOSIUM

November 4, 2016

IMMUNOMEDICS RECEIVES EDISON PATENT AWARD FROM RESEARCH & DEVELOPMENT COUNCIL OF NEW JERSEY FOR THE FOURTH TIME

November 2, 2016

IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2017 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

October 27, 2016

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FIRST QUARTER FISCAL 2017 RESULTS

October 24, 2016

IMMUNOMEDICS ENGAGES GREENHILL & CO. AS STRATEGIC ADVISOR

October 19, 2016

IMMUNOMEDICS ANNOUNCES NEW PATENTS FOR ANTIBODY-DRUG CONJUGATES AND VACCINES FOR CANCER THERAPY

October 12, 2016

IMMUNOMEDICS ANNOUNCES CLOSING OF $30 MILLION FINANCING

October 5, 2016

IMMUNOMEDICS ANNOUNCES $30 MILLION FINANCING

August 31, 2016

IMMUNOMEDICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

August 18, 2016

PRECLINICAL STUDY ON ENHANCING SACITUZUMAB GOVITECAN (IMMU-132) ACTIVITY IN SN-38-RESISTANT CANCER CELLS PUBLISHED

August 17, 2016

IMMUNOMEDICS ANNOUNCES FISCAL 2016 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

August 11, 2016

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FOURTH QUARTER AND FISCAL YEAR 2016 FINANCIAL RESULTS

June 28, 2016

IMMUNOMEDICS ANNOUNCES NEW U.S. PATENT FOR SACITUZUMAB GOVITECAN (IMMU-132) ANTIBODY-DRUG CONJUGATE (ADC)

June 21, 2016

IMMUNOMEDICS APPOINTS MICHAEL R. GARONE AS NEW CHIEF FINANCIAL OFFICER

June 7, 2016

IMMUNOMEDICS TO PRESENT AT JEFFERIES 2016 GLOBAL HEALTHCARE CONFERENCE

June 6, 2016

IMMUNOMEDICS’ SACITUZUMAB GOVITECAN (IMMU-132) DEMONSTRATES EFFICACY AND SAFETY IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH MULTIPLE PRIOR TREATMENTS, INCLUDING IMMUNO-ONCOLOGY

June 6, 2016

IMMUNOMEDICS ANNOUNCES SACITUZUMAB GOVITECAN (IMMU-132) IS ACTIVE IN PATIENTS WITH PREVIOUSLY-TREATED METASTATIC SMALL-CELL LUNG CANCER

June 3, 2016

IMMUNOMEDICS PROVIDES UPDATE ON TRIPLE-NEGATIVE BREAST CANCER PRESENTATION AT ASCO

May 19, 2016

IMMUNOMEDICS TO REPORT UPDATED RESULTS FOR SACITUZUMAB GOVITECAN (IMMU-132) IN BREAST AND LUNG CANCERS AT CLINICAL SCIENCE SYMPOSIA OF 2016 ASCO ANNUAL MEETING

May 4, 2016

IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2016 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

May 2, 2016

IMMUNOMEDICS ANNOUNCES ABSTRACT ON SACITUZUMAB GOVITECAN (IMMU-132) IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER SELECTED FOR BEST OF ASCO PROGRAM

April 29, 2016

IMMUNOMEDICS REPORTS RESPONSES WITH SACITUZUMAB GOVITECAN (IMMU-132) IN PATIENTS WITH METASTATIC SOLID CANCERS WHO FAILED PRIOR CHECKPOINT-INHIBITOR THERAPY

April 28, 2016

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR THIRD QUARTER FISCAL 2016 FINANCIAL RESULTS

April 22, 2016

IMMUNOMEDICS APPOINTS DR. SOL J. BARER SPECIAL ADVISOR TO THE CHAIRMAN

April 20, 2016

IMMUNOMEDICS AWARDED U.S. PATENT FOR NOVEL IMMUNOONCOLOGY AGENTS FOR CANCER THERAPY

April 19, 2016

IMMUNOMEDICS REPORTS SACITUZUMAB GOVITECAN (IMMU-132) SHOWS SIGNIFICANT CLINICAL ACTIVITY IN METASTATIC UROTHELIAL CANCER

April 18, 2016

IMMUNOMEDICS PRESENTS UPDATED PHASE 2 RESULTS WITH LABETUZUMAB GOVITECAN (IMMU-130) IN PATIENTS WITH METASTATIC COLORECTAL CANCER

April 18, 2016

IMMUNOMEDICS ANNOUNCES POTENT ANTI-TUMOR ACTIVITIES WITH IMMU-114 IN PRECLINICAL STUDY IN ACUTE AND CHRONIC LEUKEMIA

March 17, 2016

IMMUNOMEDICS TO PRESENT UPDATED CLINICAL TRIAL RESULTS FOR ANTIBODY-DRUG CONJUGATES AT CANCER CONFERENCE

March 14, 2016

IMMUNOMEDICS PROVIDES UPDATE ON PHASE 3 PANCRIT-1 TRIAL OF CLIVATUZUMAB TETRAXETAN IN PATIENTS WITH ADVANCED PANCREATIC CANCER

March 8, 2016

IMMUNOMEDICS DEVELOPS NOVEL ANTIBODY-BASED PRODUCTS FOR AUTOIMMUNE DISEASE AND CANCER THERAPY

March 2, 2016

IMMUNOMEDICS TO PRESENT AT COWEN AND COMPANY 36TH ANNUAL HEALTH CARE CONFERENCE

February 26, 2016

IMMUNOMEDICS ANNOUNCES TERMINATION OF EPRATUZUMAB LICENSING AGREEMENT WITH UCB

February 5, 2016

U.S. FOOD AND DRUG ADMINISTRATION (FDA) GRANTS BREAKTHROUGH THERAPY DESIGNATION TO IMMUNOMEDICS FOR SACITUZUMAB GOVITECAN FOR THE TREATMENT OF PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER

February 3, 2016

IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2016 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

January 28, 2016

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR SECOND QUARTER FISCAL 2016 FINANCIAL RESULTS

January 5, 2016

IMMUNOMEDICS ANNOUNCES NEW PATENT COVERING THE USE OF ANTIBODY-SN-38 CONJUGATES COMBINATION